|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
Nanoparticles and new technologies enhance the bioavailability of poorly soluble drugs, writes Yann Bayeux at Pierre Fabre Medicament
Around two thirds of the products used in the pharmaceutical industry are in solid form, such as tablets and pills. Consequently, a lot of effort has been put into research on particle generation processes. The standard processes – crushing/milling and crystallisation/precipitation – are still the most commonly used. However, supercritical fluid (SCF) technologies present a new and interesting route for particle formation, which avoids most of the drawbacks of the traditional methods. Supercritical processes give micro or even nanoparticles with a narrow size distribution. They can also be used in co-process with excipients or host molecules like cyclodextrins.
USING SUPERCRITICAL CO2
The supercritical state is also known as the fourth state of matter. Above a certain critical temperature and pressure (30.7°C and 73.8 bar respectively for CO2), the boundaries between gas and liquid disappear. Beyond this critical point, the substance has the viscosity of a gas and the density of a liquid. Supercritical CO2 (scCO2) is the most commonly-used system in nanoparticle generation. The main reason is linked to the intrinsic solvent properties of the supercritical CO2: the viscosity of a gas, the density of liquid and the fact that the critical state of CO2 can be easily reached. The treatment is generally carried out at about 40°C and it allows us to handle temperature-sensitive molecules. Furthermore, CO2 is cheap, non-toxic, noninflammable, easily available and can also be recycled. Supercritical carbon dioxide is considered as a ‘green’ solvent; after depressurisation, it leaves no residue, unlike an organic solvent. |
Read full article from PDF >>
|
 |
 |
 |
Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | |
|
|
 |
News and Press Releases |
 |
Stevanato Group signs an agreement with Nelson Labs to provide best-in-class Extractables and Leachables testing services at its US Technology Excellence Center
Piombino Dese, Padua Italy and Salt Lake City, USA September 2, 2020:
Italian-based Stevanato Group, a leading producer of glass primary
packaging and provider of integrated services for combination products,
and Nelson Laboratories, LLC, a global provider of lab testing and
expert advisory services signed today a partnership agreement that will
provide Extractables and Leachables testing at SG US Technology
Excellence Center in Boston, MA.
More info >> |
|

 |
White Papers |
 |
Maximize the ROI of Your Post-Approval Research
Bioclinica
Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment.
Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >> |
|
|